近日，海正药业与九州通医药集团正式签署战略合作协议，标志着双方在医药研发、生产与流通领域的深度协同迈出关键一步。作为国内领先的创新型制药企业，海正药业在抗肿瘤、抗感染、心血管及生物药等领域拥有雄厚的研发实力和丰富的产品管线；而九州通则是中国最大的民营医药流通企业之一，具备覆盖全国的高效物流网络和强大的终端渠道资源。此次合作将充分发挥海正药业的创新药研产优势与九州通的供应链及市场拓展能力，共同推动优质药品更快、更广地惠及患者。双方将在产品分销、院外市场开发、数字化营销、慢病管理等多个维度展开全方位合作，并探索在创新药商业化、基层医疗市场渗透等新兴领域的协同发展模式。此举不仅有助于提升海正药业产品的市场覆盖率和可及性，也将强化九州通在高附加值处方药和创新药配送领域的服务能力，实现互利共赢。业内普遍认为，该战略合作顺应了医药产业‘研产销一体化’的发展趋势，有望为行业树立上下游高效协同的新标杆。
Recently, Hisun Pharmaceutical and Joincare Pharmaceutical Group officially signed a strategic cooperation agreement, marking a significant step toward deeper collaboration between the two companies in pharmaceutical R&D, manufacturing, and distribution. Hisun, a leading innovative Chinese pharmaceutical company, boasts strong R&D capabilities and a robust pipeline in areas such as oncology, anti-infectives, cardiovascular diseases, and biologics. Joincare, one of China’s largest private pharmaceutical distributors, offers an extensive nationwide logistics network and powerful downstream channel resources. This partnership will leverage Hisun’s strengths in innovative drug development and production alongside Joincare’s supply chain efficiency and market reach to accelerate and broaden patient access to high-quality medicines. The two parties plan comprehensive collaboration across product distribution, out-of-hospital market expansion, digital marketing, and chronic disease management, while also exploring synergies in commercializing innovative drugs and penetrating primary healthcare markets. The alliance is expected to enhance Hisun’s market coverage and drug accessibility while strengthening Joincare’s capabilities in distributing high-value prescription and innovative medicines—creating mutual benefits. Industry observers view this strategic move as aligned with the growing trend of integrated R&D, manufacturing, and sales in China’s pharmaceutical sector, potentially setting a new benchmark for efficient upstream-downstream collaboration.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/2374.html